About Tumor necrosis factor receptor superfamily member 27
Tumor necrosis factor receptor superfamily member 27 (EDA2R) is a protein
from Homo sapiens identified by UniProt accession
Q9HAV5, 297 residues long.
MolForge cross-references it against 0 known binders and
78 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 27 |
|---|
| UniProt accession | Q9HAV5 |
|---|
| Gene | EDA2R |
|---|
| Organism | Homo sapiens |
|---|
| Length | 297 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (78)
Diseases linked to this target (Open Targets).
- X-linked hypohidrotic ectodermal dysplasia · score 0.40
- neurodegenerative disease · score 0.23
- metabolic disease · score 0.19
- endocrine system disease · score 0.19
- nutritional disorder · score 0.19
- hypertension · score 0.16
- uric acid measurement · score 0.13
- creatinine measurement · score 0.13
- Varicose veins · score 0.09
- gonorrhea · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9HAV5-F1 | alphafold | PREDICTED | 68.83 | — |
Amino-acid sequence (297 residues)
MDCQENEYWD QWGRCVTCQR CGPGQELSKD CGYGEGGDAY CTACPPRRYK SSWGHHRCQS CITCAVINRV QKVNCTATSN AVCGDCLPRF YRKTRIGGLQ DQECIPCTKQ TPTSEVQCAF QLSLVEADTP TVPPQEATLV ALVSSLLVVF TLAFLGLFFL YCKQFFNRHC QRGGLLQFEA DKTAKEESLF PVPPSKETSA ESQVSENIFQ TQPLNPILED DCSSTSGFPT QESFTMASCT SESHSHWVHS PIECTELDLQ KFSSSASYTG AETLGGNTVE STGDRLELNV PFEVPSP
Explore Tumor necrosis factor receptor superfamily member 27 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets